Why the study?
Does extended-duration oral betrixaban reduce the risk of venous thromboembolism compared to standard-duration enoxaparin in patients hospitalized for acute medical illness?
RCT (n=7,513)
Double-blind, double-dummy
1:1
Yes
Does extended-duration oral betrixaban reduce the risk of venous thromboembolism compared to standard-duration enoxaparin in patients hospitalized for acute medical illness?
Extended-duration betrixaban showed potential to reduce VTE events compared to standard-duration enoxaparin in acutely ill medical patients, though primary hierarchical testing failed at the first step.
Answers are grounded in this paper and cite their sources.
May reduce VTE in select medical inpatients; leaves open confirmatory RCTs after hierarchical testing failure.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.
No takes yet. Share an insight, caveat, or question.
Danial E. Baker (2017) conducted an RCT in Acute medical illness with risk factors for venous thromboembolism (n=7,513). Betrixaban vs. Enoxaparin 40 mg subcutaneously daily was evaluated on Composite of asymptomatic proximal DVT between days 32 and 47, symptomatic proximal or distal DVT, symptomatic nonfatal PE, or death from VTE between days 1 and 42 (overall population cohort) (RR 0.76, 95% CI 0.63-0.92, p=0.006).
Synapse has enriched 10 related papers. Consider them for comparative context: